Sionna Therapeutics anticipates sufficient cash to support operations through 2028.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
- Strong Cash Position: The company has approximately $325.0 million in cash and cash equivalents.
- Funding Operations: This cash is expected to fund operations into 2028.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SION?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SION
Wall Street analysts forecast SION stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SION is 47.80 USD with a low forecast of 24.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 42.130
Low
24.00
Averages
47.80
High
60.00
Current: 42.130
Low
24.00
Averages
47.80
High
60.00
About SION
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sionna Therapeutics CLO Jennifer Fitzpatrick Sells Shares Worth $415,330
- Executive Share Sale: On December 5, 2025, Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick exercised 10,250 options and sold the shares for $415,330, indicating executive confidence in the company's stock performance.
- Holding Changes: Following the transaction, Fitzpatrick's direct ownership dropped to zero shares, yet she retains 61,185 outstanding options, which may provide future equity exposure, reflecting her ongoing commitment to the company's prospects.
- Market Performance Insight: The shares were sold at a weighted average price of approximately $40.52, slightly above the market close of $40.29 on December 5, 2025, showcasing her astute awareness of current market conditions.
- Optimistic Company Outlook: Despite having no revenue, Sionna Therapeutics has seen a 45.36% stock price increase since its IPO on February 7, 2025, demonstrating investor confidence in its future drug development for cystic fibrosis.
Continue Reading
Sionna Therapeutics CLO Sells 10,250 Shares for Over $400K
- Executive Trading Activity: On December 5, 2025, Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick exercised 10,250 options and sold them in an open-market transaction valued at $415,330, indicating executive confidence in the company's future.
- Strong Stock Performance: Since its IPO on February 7, 2025, Sionna Therapeutics' stock has surged 45.36%, reflecting investor optimism regarding its future development and clinical strategies, despite currently having zero revenue.
- Active Insider Transactions: Over the past few weeks, at least five different insiders have conducted transactions, both directly and indirectly, suggesting a positive outlook from within the company that may attract more investor interest.
- Future Development Outlook: Sionna Therapeutics plans to continue developing clinical strategies to combat cystic fibrosis through 2028 and claims to have strong financial backing, laying a foundation for long-term growth.
Continue Reading